[{"id":"3d25c448-acf8-4e6b-a932-342422e06f4f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06908304","created_at":"2025-09-07T01:12:54.209Z","updated_at":"2025-09-07T01:12:54.209Z","phase":"Phase 3","brief_title":"A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC","source_id_and_acronym":"NCT06908304","lead_sponsor":"Maia Biotechnology","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • docetaxel • Libtayo (cemiplimab-rwlc) • vinorelbine tartrate • ateganosine (THIO)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 07/28/2025","start_date":" 07/28/2025","primary_txt":" Primary completion: 07/29/2026","primary_completion_date":" 07/29/2026","study_txt":" Completion: 07/29/2027","study_completion_date":" 07/29/2027","last_update_posted":"2025-04-08"},{"id":"8f439945-e5eb-40b9-a7e6-6eb64cdd7790","acronym":"","url":"https://clinicaltrials.gov/study/NCT01409161","created_at":"2021-01-18T05:47:46.957Z","updated_at":"2025-02-25T17:35:27.084Z","phase":"Phase 2","brief_title":"Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT01409161","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" RARA • PML","pipe":"","alterations":" ","tags":["RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • Vesanoid (tretinoin) • arsenic trioxide"],"overall_status":"Recruiting","enrollment":" Enrollment 151","initiation":"Initiation: 10/05/2011","start_date":" 10/05/2011","primary_txt":" Primary completion: 12/18/2025","primary_completion_date":" 12/18/2025","study_txt":" Completion: 12/18/2025","study_completion_date":" 12/18/2025","last_update_posted":"2025-01-28"},{"id":"0388c28a-65ca-445b-9f8d-078ae068c2a4","acronym":"THIO-101","url":"https://clinicaltrials.gov/study/NCT05208944","created_at":"2025-02-26T12:39:23.695Z","updated_at":"2025-02-26T12:39:23.695Z","phase":"Phase 2","brief_title":"THIO Sequenced with Cemiplimab in Advanced NSCLC","source_id_and_acronym":"NCT05208944 - THIO-101","lead_sponsor":"Maia Biotechnology","biomarkers":" IL6 • CRP","pipe":"","alterations":" ","tags":["IL6 • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • ateganosine (THIO)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 182","initiation":"Initiation: 06/08/2022","start_date":" 06/08/2022","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 10/31/2026","study_completion_date":" 10/31/2026","last_update_posted":"2024-11-22"},{"id":"dfbc062f-ed24-4f40-8bd7-edd7973cf532","acronym":"","url":"https://clinicaltrials.gov/study/NCT04919369","created_at":"2021-06-10T01:52:31.476Z","updated_at":"2024-07-02T16:35:14.922Z","phase":"Phase 1","brief_title":"All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04919369","lead_sponsor":"Dwight Owen","biomarkers":" PD-L1 • ALK","pipe":"","alterations":" ","tags":["PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Vesanoid (tretinoin)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 10/18/2021","start_date":" 10/18/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-13"},{"id":"2aab645e-82e6-4871-a584-636d0a665d5d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04897490","created_at":"2021-05-21T11:52:52.627Z","updated_at":"2024-07-02T16:35:24.138Z","phase":"","brief_title":"RWE of 1st Line Treatment With ATO/ATRA for Adult APL","source_id_and_acronym":"NCT04897490","lead_sponsor":"Grupo Argentino de Tratamiento de la Leucemia Aguda","biomarkers":" BCR","pipe":" | ","alterations":" FLT3 mutation","tags":["BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vesanoid (tretinoin) • arsenic trioxide"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 03/01/2021","start_date":" 03/01/2021","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-01-09"},{"id":"df5b5086-1697-4c00-8ecc-c22d551b5706","acronym":"","url":"https://clinicaltrials.gov/study/NCT02339740","created_at":"2021-01-18T11:07:04.205Z","updated_at":"2024-07-02T16:35:28.404Z","phase":"Phase 3","brief_title":"Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT02339740","lead_sponsor":"Children's Oncology Group","biomarkers":" FLT3 • RARA • PML","pipe":" | ","alterations":" FLT3 mutation • FLT3 wild-type","tags":["FLT3 • RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • mitoxantrone • Vesanoid (tretinoin) • arsenic trioxide • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 158","initiation":"Initiation: 07/21/2015","start_date":" 07/21/2015","primary_txt":" Primary completion: 10/31/2020","primary_completion_date":" 10/31/2020","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2023-11-22"},{"id":"3212545e-61a5-4679-863b-11a4f4ec1221","acronym":"ATRA","url":"https://clinicaltrials.gov/study/NCT04113863","created_at":"2021-01-18T20:06:42.396Z","updated_at":"2024-07-02T16:35:32.515Z","phase":"Phase 2","brief_title":"Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer","source_id_and_acronym":"NCT04113863 - ATRA","lead_sponsor":"Mario Negri Institute for Pharmacological Research","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anastrozole • Vesanoid (tretinoin)"],"overall_status":"Recruiting","enrollment":" Enrollment 112","initiation":"Initiation: 06/18/2019","start_date":" 06/18/2019","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-10-19"},{"id":"61ed23cb-0c39-45f9-835d-557d807f6aa9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03921021","created_at":"2021-01-18T19:17:33.481Z","updated_at":"2024-07-02T16:35:41.743Z","phase":"Phase 2","brief_title":"Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma","source_id_and_acronym":"NCT03921021","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Telomelysin (suratadenoturev)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 05/09/2019","start_date":" 05/09/2019","primary_txt":" Primary completion: 06/20/2023","primary_completion_date":" 06/20/2023","study_txt":" Completion: 07/20/2023","study_completion_date":" 07/20/2023","last_update_posted":"2023-07-27"},{"id":"dfc3a399-9a0f-4709-8f4e-69c5187b4188","acronym":"CRUKD/17/003","url":"https://clinicaltrials.gov/study/NCT03371485","created_at":"2023-03-22T18:03:32.842Z","updated_at":"2024-07-02T16:35:52.683Z","phase":"Phase 1","brief_title":"AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03371485 - CRUKD/17/003","lead_sponsor":"Cancer Research UK","biomarkers":" TERT","pipe":"","alterations":" ","tags":["TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VAC2"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 06/01/2018","start_date":" 06/01/2018","primary_txt":" Primary completion: 08/08/2022","primary_completion_date":" 08/08/2022","study_txt":" Completion: 08/08/2022","study_completion_date":" 08/08/2022","last_update_posted":"2023-03-22"},{"id":"e5587414-ede2-4832-a20e-9bd4ff957340","acronym":"","url":"https://clinicaltrials.gov/study/NCT03031249","created_at":"2021-01-18T14:55:11.899Z","updated_at":"2024-07-02T16:36:47.929Z","phase":"Phase 1/2","brief_title":"Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia","source_id_and_acronym":"NCT03031249","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital","biomarkers":" NPM1","pipe":" | ","alterations":" NPM1 mutation","tags":["NPM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Vesanoid (tretinoin) • arsenic trioxide"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 02/08/2017","start_date":" 02/08/2017","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2020-03-20"},{"id":"0dd3a28d-1be7-40ff-a066-40868ec0b07e","acronym":"KG 4/2015","url":"https://clinicaltrials.gov/study/NCT02854072","created_at":"2021-01-18T14:00:33.938Z","updated_at":"2024-07-02T16:37:27.514Z","phase":"Phase 3","brief_title":"A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients","source_id_and_acronym":"NCT02854072 - KG 4/2015","lead_sponsor":"Samsung Pharmaceutical Co., Ltd.","biomarkers":" CCL11 • CA 19-9","pipe":"","alterations":" ","tags":["CCL11 • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • capecitabine • LucaVax (tertomotide)"],"overall_status":"Unknown status","enrollment":" Enrollment 148","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 05/01/2018","primary_completion_date":" 05/01/2018","study_txt":" Completion: 05/01/2018","study_completion_date":" 05/01/2018","last_update_posted":"2016-11-22"}]